CN101873852A - 治疗视黄醇相关性疾病的方法和化合物 - Google Patents

治疗视黄醇相关性疾病的方法和化合物 Download PDF

Info

Publication number
CN101873852A
CN101873852A CN200880107835A CN200880107835A CN101873852A CN 101873852 A CN101873852 A CN 101873852A CN 200880107835 A CN200880107835 A CN 200880107835A CN 200880107835 A CN200880107835 A CN 200880107835A CN 101873852 A CN101873852 A CN 101873852A
Authority
CN
China
Prior art keywords
alkyl
formula
compound
optionally substituted
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880107835A
Other languages
English (en)
Chinese (zh)
Inventor
内森·L·马塔
金·B·潘
塔姆·V·布伊
穆斯塔法·哈达赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirion Therapeutics Inc
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of CN101873852A publication Critical patent/CN101873852A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200880107835A 2007-09-27 2008-09-16 治疗视黄醇相关性疾病的方法和化合物 Pending CN101873852A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97576507P 2007-09-27 2007-09-27
US60/975,765 2007-09-27
US98132207P 2007-10-19 2007-10-19
US60/981,322 2007-10-19
PCT/US2008/076499 WO2009042444A2 (en) 2007-09-27 2008-09-16 Methods and compounds for treating retinol-related diseases

Publications (1)

Publication Number Publication Date
CN101873852A true CN101873852A (zh) 2010-10-27

Family

ID=40512081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880107835A Pending CN101873852A (zh) 2007-09-27 2008-09-16 治疗视黄醇相关性疾病的方法和化合物

Country Status (8)

Country Link
EP (1) EP2205234A4 (https=)
JP (1) JP2010540541A (https=)
KR (1) KR20100097098A (https=)
CN (1) CN101873852A (https=)
AU (1) AU2008305303A1 (https=)
CA (1) CA2699773A1 (https=)
IL (1) IL204728A0 (https=)
WO (1) WO2009042444A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051244A1 (ja) 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
US8853215B2 (en) 2009-04-16 2014-10-07 Takeda Pharmaceutical Company Limited Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
JP5951625B2 (ja) * 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
WO2012074038A1 (ja) * 2010-12-02 2012-06-07 第一三共株式会社 修飾１本鎖ポリヌクレオチド
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
US9944596B2 (en) * 2014-10-24 2018-04-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102490156B1 (ko) 2014-10-24 2023-01-18 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
AU2021265838A1 (en) * 2020-04-29 2022-10-20 Saliogen Therapeutics, Inc. Compositions and methods for treatment of inherited macular degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526534A (en) * 1948-07-03 1950-10-17 Dow Chemical Co Di-(aryloxy)-methanes
US4255152A (en) * 1978-09-05 1981-03-10 Ciba-Geigy Corporation Process for the dyeing of hydrophobic fibres
JPS577480A (en) * 1980-06-16 1982-01-14 Sankyo Co Ltd 4-alkoxy-6-phenoxymethyl-2-pyrone derivative
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
WO2005116010A1 (en) * 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof

Also Published As

Publication number Publication date
IL204728A0 (en) 2010-11-30
WO2009042444A2 (en) 2009-04-02
KR20100097098A (ko) 2010-09-02
CA2699773A1 (en) 2009-04-02
EP2205234A4 (en) 2010-12-22
JP2010540541A (ja) 2010-12-24
AU2008305303A1 (en) 2009-04-02
WO2009042444A3 (en) 2009-05-14
EP2205234A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
CN101873852A (zh) 治疗视黄醇相关性疾病的方法和化合物
US7973079B2 (en) Methods and compounds for treating retinol-related diseases
TWI396532B (zh) 用視黃基衍生物治療眼疾之方法及組合物
KR102160388B1 (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
US20200325148A1 (en) Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US11427540B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
JP5841333B2 (ja) 安定化されたカリスバメートの小児用懸濁液
CN101252924A (zh) 通过血清视黄醇、血清视黄醇结合蛋白(rbp)和/或血清视黄醇-rbp调节治疗眼部疾病的方法和组合物
CN103191129A (zh) 治疗眼睛病症的脂氧化物类化合物
JP2019142907A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
TW201038544A (en) Anti-neurodegenerative diseases agents
US20170296523A1 (en) Pharmaceutical Compositions Comprising Alpelisib
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
CN116528840B (zh) 细胞内atp增强剂
CN103153309A (zh) 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
WO2012078525A2 (en) Compositions and methods for treating ophthalmic conditions
Beriain Viguria Roles of the CB1 receptor and the endocannabinoid system in the retina
US20190201376A1 (en) Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases
CN102988331B (zh) 2-巯基-3-丁醇用于制备抗晶状体混浊产品的用途
GB2597282A (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP2320912B1 (en) Treatment of retinal degeneration
CN119587551A (zh) 厄洛替尼在制备促进视网膜色素上皮细胞移植后的整合药物中的应用
US20080033045A1 (en) Treatment of psychiatric disorders
CN106511350A (zh) 6‑羟基‑7‑芳甲酰基喹啉酮类化合物在治疗溃疡性结肠炎中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101027